Gene therapy relies on safe and efficient delivery systems, yet traditional viral vectors and synthetic polymers often fail to meet these requirements due to immunogenicity and biocompatibility concerns. This review highlights self-assembling short peptides as a highly programmable and biocompatible non-viral platform uniquely positioned to overcome these translational bottlenecks. To provide a comprehensive overview of next-generation gene delivery, we systematically trace the trajectory from fundamental chemistry to clinical applications. First, we elucidate the supramolecular interactions and mechanisms driving peptide–nucleic acid co-assembly. Second, we outline concrete design strategies, detailing how sequence engineering and environmental responsiveness dictate the formation of optimized nanomorphologies. Third, we critically analyze how these nanocarriers navigate critical physiological and intracellular barriers, with a specific focus on cellular uptake, endosomal escape, and cargo release. Finally, we demonstrate the platform’s versatility in emerging frontiers, particularly mRNA vaccines and CRISPR/Cas9 gene editing. We conclude by identifying current obstacles to clinical translation and proposing future directions centered on multifunctional integration and stimuli-responsive design.
Building similarity graph...
Analyzing shared references across papers
Loading...
Longyu An
Zhanyao Xu
Xuan Zhang
International Journal of Molecular Sciences
Minzu University of China
Building similarity graph...
Analyzing shared references across papers
Loading...
An et al. (Sun,) studied this question.
www.synapsesocial.com/papers/69df2bcae4eeef8a2a6b0bdf — DOI: https://doi.org/10.3390/ijms27083464
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: